DDInter1477 DDInter1840
Pirfenidone is a synthetic pyridone drug. It is an antifibrotic agent with anti-inflammatory and antioxidant properties that is used to treat idiopathic pulmonary fibrosis (IPF), which is a chronic, progressive form of interstitial pneumonia. While its mechanism of action is not yet fully understood, pirfenidone is proposed to primarily regulate tumor necrosis factor (TNF) pathways and modulate cellular oxidation. The FDA first approved pirfenidone alongside [nintedanib] as one of the first drugs to treat IPF.
Trabectedin, also referred as ET-743 during its development, is a marine-derived antitumor agent discovered in the Carribean tunicate _Ecteinascidia turbinata_ and now produced synthetically. Trabectedin has a unique mechanism of action. It binds to the minor groove of DNA interfering with cell division and genetic transcription processes and DNA repair machinery. It is approved for use in Europe, Russia and South Korea for the treatment of advanced soft tissue sarcoma. It is currently under evaluation for the treatment of breast cancer, prostate cancer, in addition to pediatric sarcomas. Both the European Commission and the U.S. Food and Drug Administration (FDA) have approved trabectedin as an orphan drug in soft tissue sarcomas and ovarian cancer. On October 23, 2015, the FDA approved trabectedin, (as Yondelis), for the treatment of specific soft tissue sarcomas.
Pirfenidone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Bortezomib
Bortezomib {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Trabectedin
Pirfenidone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Methoxsalen
Methoxsalen {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Trabectedin
Pirfenidone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Methoxsalen
Methoxsalen {u} (Compound) causes {v} (Side Effect) Hypersensitivity
Hypersensitivity {u} (Side Effect) is caused by {v} (Compound) Trabectedin
Pirfenidone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bedaquiline
Bedaquiline {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Trabectedin
Pirfenidone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bedaquiline
Bedaquiline {u} (Compound) causes {v} (Side Effect) Alanine aminotransferase increased
Alanine aminotransferase increased {u} (Side Effect) is caused by {v} (Compound) Trabectedin
Pirfenidone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Bortezomib
Bortezomib {u} (Compound) causes {v} (Side Effect) Weight decreased
Weight decreased {u} (Side Effect) is caused by {v} (Compound) Trabectedin
Pirfenidone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Gemfibrozil
Gemfibrozil {u} (Compound) upregulates {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Pirfenidone {u} may lead to a major life threatening interaction when taken with {v} Amiodarone
Amiodarone {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Trabectedin
Pirfenidone {u} may lead to a major life threatening interaction when taken with {v} Aminolevulinic acid
Aminolevulinic acid {u} (Compound) causes {v} (Side Effect) Angiopathy
Angiopathy {u} (Side Effect) is caused by {v} (Compound) Trabectedin
Pirfenidone {u} may lead to a major life threatening interaction when taken with {v} Vemurafenib
Vemurafenib {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Trabectedin
Pirfenidone may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Trabectedin (Compound)
Pirfenidone may cause a moderate interaction that could exacerbate diseases when taken with Methoxsalen and Methoxsalen (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Trabectedin (Compound)
Pirfenidone may cause a moderate interaction that could exacerbate diseases when taken with Methoxsalen and Methoxsalen (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Trabectedin (Compound)
Pirfenidone may cause a moderate interaction that could exacerbate diseases when taken with Bedaquiline and Bedaquiline (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Trabectedin (Compound)
Pirfenidone may cause a moderate interaction that could exacerbate diseases when taken with Bedaquiline and Bedaquiline (Compound) causes Alanine aminotransferase increased (Side Effect) and Alanine aminotransferase increased (Side Effect) is caused by Trabectedin (Compound)
Pirfenidone may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib (Compound) causes Weight decreased (Side Effect) and Weight decreased (Side Effect) is caused by Trabectedin (Compound)
Pirfenidone may cause a moderate interaction that could exacerbate diseases when taken with Gemfibrozil and Gemfibrozil (Compound) upregulates SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Pirfenidone may lead to a major life threatening interaction when taken with Amiodarone and Amiodarone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Trabectedin (Compound)
Pirfenidone may lead to a major life threatening interaction when taken with Aminolevulinic acid and Aminolevulinic acid (Compound) causes Angiopathy (Side Effect) and Angiopathy (Side Effect) is caused by Trabectedin (Compound)
Pirfenidone may lead to a major life threatening interaction when taken with Vemurafenib and Vemurafenib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Trabectedin (Compound)